The following publications are successes from the first ACT-AEC Request for Applications (RFA 1) for ongoing and active, high-impact, Canadian-led randomized controlled trials (RCTs) that required additional funding:


ARTESIA – Healey JS, Lopes RD, Granger CB, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N Engl J Med. Published online November 12, 2023. doi:10.1056/NEJMoa2310234

  • This trial investigates the efficacy and safety of apixaban, an oral anticoagulant, in preventing stroke in patients with subclinical atrial fibrillation.
  • Click here for access


COP-AF – Conen D, Popova E, Cata JP, et al. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. The Lancet (British Edition), 2023;402(10413): 1627–1635. doi:10.1016/S0140-6736(23)01689-6

  • This trial was performed at 45 sites in 11 countries to determine the efficacy of Colchicine, an anti-inflammatory drug that might reduce the incidence of inflammatory biomarkers after non-cardiac surgery (MINS).
  • Click here for access
EnAKT LKD Garg AX, Yohanna S, Naylor KL, et al. Effect of a Novel Multicomponent Intervention to Improve Patient Access to Kidney Transplant and Living Kidney Donation: The EnAKT LKD Cluster Randomized Clinical Trial. JAMA Intern Med. 2023;183(12):1366-1375. doi:10.1001/jamainternmed.2023.5802
  • This trial determines if the use of a novel multicomponent intervention helps transplant-eligible patients complete key steps towards receiving a kidney transplant. 
  • Click here for access